Published in final edited form as:

Org Lett. 2012 March 2; 14(5): 1242–1245. doi:10.1021/ol3000519.

Stereoselective Synthesis of *cis*-2,5-Disubstituted Pyrrolidines via Wacker-Type Aerobic Oxidative Cyclization of Alkenes with *t*Bu-Sulfinamide Nucleophiles

Joanne E. Redford, Richard I. McDonald, Matthew L. Rigsby, Joshua D. Wiensch, and Shannon S. Stahl

University of Wisconsin–Madison, 1101 University Avenue, Madison, WI 53706

Shannon S. Stahl: stahl@chem.wisc.edu

Abstract

Palladium(II)-catalyzed aerobic oxidative cyclization of alkenes with tethered *tert*-butanesulfinamides furnishes enantiopure 2,5-disubstituted pyrrolidines, originating from readily available and easily diversified starting materials. These reactions are the first reported examples of metal-catalyzed addition of sulfinamide nucleophiles to alkenes.

2,5-Disubstituted pyrrolidines are an important class of heterocycles featured in numerous natural products, pharmaceuticals, ligands for transition metals, and organocatalysts.¹ Pd^{II}-catalyzed aerobic oxidative cyclization reactions provide efficient routes to pyrrolidines (eq 1);^{2,3} however, few of these methods enable

(1)

stereoselective C–N bond formation. The first examples of enantioselective oxidative cyclization have been reported only recently.^{4–6} Here, we show that chiral γ -aminoalkene substrates bearing a *t*Bu-sulfinyl auxiliary undergo efficient Pd^{II}-catalyzed aerobic oxidative cyclization to afford enantiopure 2,5-disubstituted pyrrolidines.⁷ *t*Bu-Sulfinamides have been used extensively for the stereoselective synthesis of amines, as summarized in an extensive recent review by Ellman;⁸ however, the present reactions are the first use of sulfinamides in metal-catalyzed nucleophilic functionalization of alkenes.⁹

Correspondence to: Shannon S. Stahl, stahl@chem.wisc.edu.

Supporting Information Available Experimental procedures, ¹H and ¹³C NMR spectra, and methods for determination of configuration. This material is available free of charge via the Internet at <http://pubs.acs.org>.

Our strategy to prepare 2,5-disubstituted pyrrolidines is illustrated in Scheme 1 and begins with readily available *cis*-4-hexen-1-ols.¹⁰ Aerobic oxidation of the alcohol¹¹ and condensation of the resulting aldehyde with ^tBu-sulfinamide^{8,12} furnishes the sulfinyl imine derivative **1**. Methods for stereoselective addition of nucleophiles to chiral sulfinyl imines provide access to a variety of enantiopure α -substituted sulfinamides **2**.⁸ Pd^{II}-catalyzed aerobic oxidative cyclization of **2** affords the desired 2,5-disubstituted pyrrolidines.

The enantiopure α -Me-substituted sulfinamide **3** was used as the substrate in the development of a suitable heterocyclization catalyst (Table 1).¹³ Testing of catalyst systems that have been shown previously to promote aerobic oxidative cyclization of γ -aminoalkene derivatives led to mixed results (Table 1, entries 1–4).^{3,14} Good product yields were obtained with Pd^{II} catalysts in which DMSO was used as a solvent and/or ligand (entries 1 and 4),^{3a,14} while Pd^{II}/pyridine-based catalyst systems (entries 2 and 3)^{3b,c} afforded low yields. Further screening of anionic base additives, the Pd^{II} source, and solvents (Table 1, entries 5–11; Table S1) revealed that optimal results were obtained with Pd(TFA)₂ (TFA = trifluoroacetate) as the Pd^{II} source, one equivalent of LiOAc, and DMSO as the solvent. All conditions tested led to formation of a single diastereomeric product (>20:1 dr), affording the *cis* disubstituted pyrrolidine **4**. The sulfinamide group is readily removed upon treatment of **4** with 4 M HCl,¹⁵ affording the HCl salt of the unprotected pyrrolidine in 95 % yield.¹⁶

The presence of two stereocenters in **3**, one associated with the sulfinyl group and the other α to the nitrogen atom, raises fundamental questions concerning the origin of stereocontrol in these reactions. The optimized catalyst system was used to probe these issues (Table 2). Substrate **5**, which lacks a stereocenter adjacent to nitrogen, underwent cyclization with 7:1 dr (68% yield, entry 1), demonstrating that the ^tBu-sulfinyl group could be used as an auxiliary to achieve stereocontrol when no other stereocenters are present in the substrate. The influence of the α -Me group on diastereoselectivity was evaluated by performing the cyclization of **6**, in which the ^tBu-sulfinyl group was replaced with an achiral toluenesulfonyl (Ts) group. This reaction afforded the *cis*-pyrrolidine product with moderate diastereoselectivity (6:1 dr, entry 2). The cooperative effect of the two stereocenters is evident from the improved yield and diastereoselectivity in the cyclization of the parent substrate **3** (98% yield, >20:1 dr; entry 3). The pairwise influence of the sulfur- and carbon-based stereocenters was analyzed further by testing the reaction of *epi*-**3**, in which the stereochemical configuration α to nitrogen is inverted (entry 4). This substrate afforded the corresponding *cis*-pyrrolidine¹⁶ as a single diastereomer, but with moderately reduced yield relative to the reaction of **3**. This observation suggests that rotation about the N–S bond enables the sulfinamide to act cooperatively with either epimeric form of the substrate to enforce highly diastereoselective C–N bond formation. Finally, analysis of the alkene stereochemistry revealed that significantly lower yield and diastereoselectivity was observed with substrate **7**, bearing a *trans*-alkene (cf. entries 3 and 5).¹⁷

With these results in hand, we investigated the reactivity of a number of different substrates (Table 3). A benzyl-substituted alkene underwent cyclization in 85% yield to provide the styrenyl product (entry 1). Each of the other substrates, bearing diverse functional groups in the α position, was readily obtained by stereoselective addition of the appropriate nucleophile to the sulfinylimine precursor (cf. Scheme 1).^{8,16} Oxidative cyclization of these substrates proceeded with excellent diastereoselectivity, in most cases affording a single detectable diastereomer (Table 3). All of the reactions proved to be operationally straightforward, with substrates and reagents weighed and combined in a flask open to the air and stirred under a balloon of O₂. Substrates with relatively large α substituents, including isopropyl and aryl groups, proceeded effectively, albeit with a somewhat lower yield relative to the α -Me derivative **3** (61–74% yield, entries 2–4). Substrates featuring an aryl chloride (entry 4), phosphonate (entry 5), carboxylic ester (entry 6), or acetal (entry 7)

also underwent successful cyclization. The latter functional groups are appealing because they are readily amenable to further functional-group manipulations to prepare more complex molecules.

Substrate **8**, which contains an α -propenyl substituent, cyclized in good yield with increased temperature and O₂ pressure (Table 3, entry 8). Alkene metathesis of the diene product **9** using the Grubbs II catalyst yielded the azabicyclic tropene **10** in 82% yield (Scheme 2).¹⁶ Tropane alkaloids have received substantial attention in recent years due to the effect of these molecules on the central nervous system,¹⁸ and tropene derivatives directly analogous to **10** have been converted by straightforward methods to various alkaloid products.^{18d}

In summary, we have developed catalytic conditions that enable Wacker-type aerobic oxidative cyclization of alkenes bearing tethered ^tBu-sulfinamide nucleophiles. These reactions benefit from efficient access to the enantiopure substrates and highly diastereoselective cyclization, and they enable modular, stereocontrolled synthesis of a diverse collection of *cis*-2,5-disubstituted pyrrolidines. These results highlight the prospective utility of ^tBu-sulfinamides as chiral nitrogen nucleophiles in metal-catalyzed additions to alkenes and related electrophiles.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank the NIH (R01 GM67163) and Abbott Laboratories (graduate fellowship for R.I.M) for financial support. Spectroscopic instrumentation was partially funded by the NSF (CHE-9208463, CHE-0342998, CHE-9629688, CHE-9974839), and high-pressure instrumentation was funded by the NSF (CHE-0946901).

References

1. (a) Ronzani N, Lajat M. *Bioorg Med Chem Lett*. 1995; 5:1131–1132. (b) O'Hagan D. *Nat Prod Rep*. 2000; 17:435–446. [PubMed: 11072891] (c) Wright SW, Ammirati MJ, Andrews KM, Brodeur AM, Danley DE, Doran SD, Lillquist JS, McClure LD, McPherson RK, Orena SJ, Parker JC, Polivkova J, Qiu X, Soeller WC, Soglia CB, Treadway JL, VanVolkenburg MA, Wang H, Wilder DC, Olson TV. *J Med Chem*. 2006; 49:3068–3076. [PubMed: 16722626] (d) Sionini V, Benaglia M, Pignataro L, Guizzetti S, Celentano G. *Synlett*. 2008; 7:1061–1065. (e) Grynkiewicz G, Gadzikowska M. *Pharmacol Rep*. 2008; 60:439–463. [PubMed: 18799813] (f) Chen H, Sweet JA, Lam KC, Rheingold AL, McGrath DV. *Tetrahedron Asymm*. 2009; 20:1672–1682.
2. For reviews, see: (a) Hegedus LS, Semmelhack MF. *Comprehensive Organic Synthesis*. Pergamon Press, Inc Elmsford 1991; 4:551–569. (b) Hosokawa T, Murahashi S-I, Negishi E, de Meijere A. *Handbook of Organopalladium Chemistry for Organic Synthesis*. John Wiley and Sons, Inc New York 2002; 2:2169–2192. (c) Hosokawa T, Negishi E, de Meijere A. *Handbook of Organopalladium Chemistry for Organic Synthesis*. John Wiley and Sons, Inc New York 2002; 2:2211–2225. (d) Zeni G, Larock RC. *Chem Rev*. 2004; 104:2285–2309. [PubMed: 15137792] (e) Stahl SS. *Angew Chem, Int Ed*. 2004; 43:3400–3420. (f) Beccalli EM, Brogini G, Martinelli M, Sottocornola S. *Chem Rev*. 2007; 107:5318–5365. [PubMed: 17973536] (g) Minatti A, Muñiz K. *Chem Soc Rev*. 2007; 36:1142–1152. [PubMed: 17576481] (h) Kotov V, Scarborough CC, Stahl SS. *Inorg Chem*. 2007; 46:1910–1923. [PubMed: 17348722]
3. For the development of aerobic catalyst systems for the synthesis of pyrrolidines, see: a) Larock RC, Hightower TR, Hasvold LA, Peterson KP. *J Org Chem*. 1996; 61:3584–3584. [PubMed: 11667199] (b) Fix SR, Brice JL, Stahl SS. *Angew Chem, Int Ed*. 2002; 41:164–166. (c) Trend RM, Ramtohl YK, Ferreira EM, Stoltz BM. *Angew Chem Int Ed*. 2003; 42:2892–2895. (d) Rogers MM, Wendlandt JE, Guzei IA, Stahl SS. *Org Lett*. 2006; 8:2257–2260. [PubMed: 16706500]

4. (a) Yip KT, Yang M, Law KL, Zhu NY, Yang D. *J Am Chem Soc.* 2006; 128:3130–3131. [PubMed: 16522078] (b) He W, Yip KT, Zhu NY, Yang D. *Org Lett.* 2009; 11:5626–5628. [PubMed: 19905004] (c) Scarborough CC, Bergant A, Sazama GT, Guzei IA, Spencer LC, Stahl SS. *Tetrahedron.* 2009; 65:5084–5092. [PubMed: 20161255] (d) Jiang F, Wu Z, Zhang W. *Tetrahedron Lett.* 2010; 51:5124–5126. (e) McDonald RI, White PB, Weinstein AB, Tam CP, Stahl SS. *Org Lett.* 2011; 13:2830–2833. [PubMed: 21534607]
5. For a review of stereoselective nucleopalladation reactions, including oxidative cyclizations, see: McDonald RI, Liu G, Stahl SS. *Chem Rev.* 2011; 111:2981–3019. [PubMed: 21428440]
6. For leading references to other enantioselective metal-catalyzed aminocyclization reactions, see: (a) Hong S, Tian S, Metz MV, Marks TJ. *J Am Chem Soc.* 2003; 125:14768–14783. [PubMed: 14640652] (b) Wood MC, Leitch DC, Yeung CS, Kozak JA, Schafer LL. *Angew Chem Int Ed.* 2007; 46:354–358. (c) Chemler SR. *Org Biomol Chem.* 2009; 7:3009–3019. [PubMed: 20976023] (d) Fuller PH, Kim JW, Chemler SR. *J Am Chem Soc.* 2008; 130:17638–17639. [PubMed: 19049311] (e) Shen X, Buchwald SL. *Angew Chem, Int Ed.* 2010; 49:564–567. (f) Mai DN, Wolfe JP. *J Am Chem Soc.* 2010; 132:12157–12159. [PubMed: 20718417]
7. For leading references on the synthesis of 2,5-disubstituted pyrrolidines see: (a) Pichon M, Figadere B. *Tetrahedron: Asymmetry.* 1996; 7:927–964. (b) Rudolph AC, Machauer R, Martin SF. *Tet Lett.* 2004; 45:4895–4898. (c) Hussaini SR, Moloney MG. *Org Biomol Chem.* 2006; 4:2600–2615. [PubMed: 16791325] (d) Llamas T, Arrayás RG, Carretero JC. *Org Lett.* 2006; 8:1795–1798. [PubMed: 16623553] (e) Wang PA, Xu ZS, Chen CF, Gao XG, Sun XL, Zhang SY. *Chirality.* 2007; 19:581–588. [PubMed: 17508396] (f) Zhang SH, Xu L, Miao L, Shu H, Trudell ML. *J Org Chem.* 2007; 72:3133–3136. [PubMed: 17362042] (g) Paderes MC, Chemler SR. *Org Lett.* 2009; 11:1915–1918. [PubMed: 19331361] (h) Lygo B, Beynon C, McLeod MC, Roy CE, Wade CE. *Tetrahedron.* 2010; 66:8832–8836. (i) Lemen GS, Wolfe JP. *Org Lett.* 2010; 12:2322–2325. [PubMed: 20405853] (j) Lemen GS, Wolfe JP. *Org Lett.* 2011; 13:3218–3221. [PubMed: 21604733]
8. Robak MT, Herbage MA, Ellman JA. *Chem Rev.* 2010; 110:3600–3740. [PubMed: 20420386]
9. For alternative heterocyclization methods using ^tBu-sulfinamides in the stereoselective formation of C–N bonds, see: (a) Brinner KM, Ellman JA. *Org Biomol Chem.* 2005; 3:2109–2113. [PubMed: 15917897] (b) Li Y, Ni C, Liu J, Zhang L, Zheng J, Zhu L, Hu J. *Org Lett.* 2006; 8:1693–1996. [PubMed: 16597143] (c) Reddy LR, Das SG, Lui Y, Prashad M. *J Org Chem.* 2010; 75:2236–2246. [PubMed: 20201593]
10. Wenkert E, Michelotti EL, Swindell CS, Tingoli M. *J Org Chem.* 1984; 49:4894–4899.
11. Hoover JM, Stahl SS. *J Am Chem Soc.* 2011; 133:16901–16910. [PubMed: 21861488]
12. Liu GC, Cogan DA, Owens TD, Tang TP, Ellman JA. *J Org Chem.* 1999; 64:1278–1284.
13. Additional reaction optimization data is provided in the Supporting Information.
14. McDonald RI, Stahl SS. *Angew Chem Int Ed.* 2010; 49:5529–5532.
15. Cogan DA, Liu G, Ellman J. *Tetrahedron.* 1999; 55:8883–8904.
16. See Supporting Information for further information.
17. Recent studies suggest that C–N bond formation could proceed via cis or trans aminopalladation of the alkene, and further work will be needed to resolve this issue for the present reactions. Nevertheless, the results in Tables 2 and 3 demonstrate that the diastereoselectivity of these reactions is predictable from the substrate structure. For consideration of the factors that influence cis vs. trans aminopalladation of alkenes, see ref. 5 and the following leading references: (a) Wolfe JP, Nakhla JS, Kampf JW. *J Am Chem Soc.* 2006; 128:2893–2901. [PubMed: 16506768] (b) Liu GS, Stahl SS. *J Am Chem Soc.* 2007; 129:6328–6335. [PubMed: 17439217] (c) Sibbald PA, Rosewall CF, Swartz RD, Michael FE. *J Am Chem Soc.* 2009; 131:15945–15951. [PubMed: 19824646]
18. (a) Aggarwal VK, Astle CJ, Rogers-Evans M. *Org Lett.* 2004; 6:1469–1471. [PubMed: 15101769] (b) Mans DM, Pearson WH. *Org Lett.* 2004; 6:3305–3308. [PubMed: 15355038] (c) Grynkiewicz G, Gadzikowska M. *Pharmacol Rep.* 2008; 60:439–463. [PubMed: 18799813] (d) Cheng GL, Wang XY, Zhu R, Shao CW, Xu JM, Hu YF. *J Org Chem.* 2011; 76:2694–2700. [PubMed: 21391709] (e) Schultz DM, Wolfe JP. *Org Lett.* 2011; 13:2962–2965. [PubMed: 21561145]

Scheme 1.
Stereoselective Synthesis of 2,5-Disubstituted Pyrrolidines

Scheme 2.

Synthesis of a Common Precursor for the Synthesis of Tropane Alkaloids

Table 1Optimization of a Catalyst System for Diastereoselective Oxidative Cyclization^a

entry	[Pd ^{II}]/additives	solvent	yield ^c
1	Pd(OAc) ₂ /2 equiv NaOAc, no 3 Å MS	DMSO	87
2	Pd(OAc) ₂ /20 mol % pyridine	toluene	38
3	Pd(TFA) ₂ /40 mol % pyridine, 2 equiv Na ₂ CO ₃ , no 3 Å MS	toluene	8
4	Pd(TFA) ₂ /20 mol % DMSO, 1 equiv LiOAc	THF	83
5	Pd(TFA) ₂ /no base	DMSO	6
6	Pd(TFA) ₂ /1 equiv NaOAc	DMSO	81
7	Pd(TFA) ₂ /1 equiv NaOBz	DMSO	79
8	Pd(TFA)₂/1 equiv LiOAc	DMSO	92
9	Pd(TFA) ₂ /1 equiv Na ₂ CO ₃	DMSO	14
10	PdCl ₂ /1 equiv LiOAc	DMSO	81
11	Pd(OPiv) ₂ /1 equiv LiOAc	DMSO	13

^a Conditions: substrate (0.08 mmol), Pd^{II} (0.008 mmol), 3 Å MS (40 mg), O₂ (1 atm), solvent (0.8 mL), 50 °C, 14 h.^b Diastereomeric ratio determined by ¹H NMR spectroscopy.^c Yield determined by ¹H NMR spectroscopy, int. std. = PhSiMe₃.

Table 2Substrate Effects on the Diastereoselectivity of Pd^{II}-Catalyzed Oxidative Cyclization^a

entry	substrate	product	yield ^b	dr ^c
1	5		68%	7:1
2	6		83%	6:1
3	3		98%	>20:1
4	<i>epi-3</i>		78%	>20:1
5	7		41%	7:1

^a Conditions: substrate (0.07 mmol), Pd(TFA)₂ (0.007 mmol), 3 Å MS (35 mg), O₂ (1 atm), DMSO-*d*₆ (0.7 mL), 50 °C, 24 h.^b Yield determined by ¹H NMR spectroscopy, int. std. = PhSiMe₃.^c Diastereomeric ratio determined by ¹H NMR spectroscopy of crude reaction mixture.

Table 3

Stereoselective Oxidative Cyclization of Alkenes Bearing Tethered α -Substituted t Bu-Sulfonamide Nucleophiles^a

entry	substrates	product	yield ^c	dr ^b
1			85%	>20:1
2			64%	>20:1
3			68%	>20:1
4			71%	>20:1
5			54%	>20:1
6			80%	>20:1
7			67%	>20:1

^a Conditions: substrate (0.5 mmol), Pd(TFA)₂ (0.05 mmol), 3 Å MS (250 mg), O₂ balloon, DMSO (5 mL), 50 °C, 24 h.

^c Isolated yield.

^b Diastereomeric ratio determined by ¹H NMR spectroscopy of crude reaction mixture.

^d Performed at 70 °C, 3 atm O₂.